clinical trials

BiomX Inc. has issued a statement addressing unusual trading activity in its stock, confirming no undisclosed material developments. The company noted recent challenges, including the discontinuation of a Phase 2b trial, cost-cutting measures, a private placement, and a reverse stock split. Despite a broader biotech sector uptick, BiomX’s shares trade below historical averages. Investor sentiment has closely followed clinical and financial news.

Revelation Biosciences is raising approximately $11 million by exercising outstanding warrants at $0.86 per share. This move also involves issuing new warrants for an additional 26,130,000 shares, contingent on stockholder approval. The capital will support the company’s clinical-stage life sciences operations. This financing strategy, while common, may lead to shareholder dilution. The market’s reaction historically has been mixed to such equity-linked financing.

ONWARD Medical has implanted its investigational ARC-BCI® Therapy in seven individuals, a significant milestone in brain-computer interface technology for spinal cord injury. This system integrates a brain implant, AI for signal decoding, and a neurostimulator to translate intended movement into functional limb motion. The therapy has received FDA Breakthrough Device Designation and is supported by substantial research grants. Further clinical trials are planned to establish broader efficacy and safety.

IDEAYA Biosciences unveiled its 2026 strategic roadmap, focusing on advancing its pipeline. Key objectives include presenting darovasertib trial results for uveal melanoma, potentially supporting accelerated approval, and initiating four registrational trials. The company will also advance its antibody-drug conjugate programs, including IDE849 for neuroendocrine cancers, and explore next-generation therapies targeting MTAP pathway alterations and CDKN2A. With substantial cash reserves extending into 2030, IDEAYA is set for significant pipeline progress and potential regulatory milestones.

AtaiBeckley Inc. has successfully redomiciled its corporate parent from the Netherlands to Delaware, U.S. This strategic move, overwhelmingly approved by shareholders, aims to enhance operational efficiency, streamline corporate structure, and better align with its U.S. investor base. The company’s stock will continue trading on Nasdaq under “ATAI.” This redomiciliation is part of AtaiBeckley’s ongoing reorganization and supports its mission to develop innovative mental health treatments.

.Terns Pharmaceuticals (NASDAQ: TERN) priced an upsized underwritten public offering of 16,250,000 common shares at $40.00 each, generating about $650 million in gross proceeds. Underwriters have a 30‑day option to purchase an additional 2,437,500 shares. The transaction is expected to close on December 11, 2025. Net proceeds will fund research, clinical trials, development, and manufacturing of the lead candidate TERN‑701, support initial launch activities, and cover working‑capital and general corporate needs.

Organon presented data at ACAAI 2025 showing VTAMA cream’s efficacy in children (2-17) with atopic dermatitis (AD). A sub-analysis of Phase 3 trials (ADORING 1 & 2) revealed early and clinically meaningful improvements in skin clearance (vIGA-AD, EASI-75), patient-reported outcomes (POEM), and itch (PP-NRS) at week 8, regardless of comorbidities like asthma or allergies. This largest pediatric VTAMA data set supports its use as a treatment option, demonstrating a favorable safety and efficacy profile.

Innate Pharma SA (IPHA) will host a conference call on November 13, 2025, to discuss its Q3 2025 business progress. Key executives will present and answer questions. The call will be webcast live and available for replay on the company website. Innate Pharma focuses on developing immunotherapies, including lacutamab, IPH4502, and monalizumab. Investors will focus on clinical trial updates, cash runway, and competitive advantages. Note the presence of forward-looking statements subject to risks detailed in company filings.

Argenx (ARGX) reported Q3 2025 global product net sales of $1.13B and total operating income of $1.15B. Operating profit reached $346M, with $4.3B in cash and financial assets. The company reaffirmed its ~$2.5B combined R&D and SG&A guidance and plans to file an sBLA for seronegative gMG by year-end 2025, with ADAPT-OCULUS results expected in 1H26. Five registrational readouts are anticipated in 2026. A FUJIFILM manufacturing partnership expanded with a new North Carolina site.